DonaldETsaiMD
Oncology • Philadelphia, PAHematologic Oncology
Associate Professor, Medicine, Perelman School of Medicine
Dr. Tsai is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3400 Spruce St
15 Penn Tower
Philadelphia, PA 19104Phone+1 215-662-3914
Education & Training
University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 1996 - 2000- University of Pennsylvania Health SystemResidency, Internal Medicine, 1994 - 1996
Duke University School of MedicineClass of 1994
Certifications & Licensure
PA State Medical License 1995 - 2024
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Study of Bexarotene in Patients With Acute Myeloid Leukemia Start of enrollment: 2004 Jan 01
- Phase II Study of Bexarotene in Patients With Acute Myeloid Leukemia Start of enrollment: 2010 May 25
Publications & Presentations
PubMed
- 4 citationsTabelecleucel for EBV+ PTLD after allogeneic HCT or SOT in a multicenter expanded access protocol.Sarah Nikiforow, Jennifer S Whangbo, Ran Reshef, Donald E Tsai, Nancy Bunin
Blood Advances. 2024-06-25 - 55 citationsPirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia.Anthony R Mato, Jennifer A Woyach, Jennifer R Brown, Paolo Ghia, Krish Patel
The New England Journal of Medicine. 2023-07-06 - 240 citationsPirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.Anthony R. Mato, Nirav N. Shah, Wojciech Jurczak, Chan Yoon Cheah, John M. Pagel
Lancet. 2021-03-06
Abstracts/Posters
- Long-Term Outcomes of Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disorder (EBV+PTLD) Following Solid Organ (SOT) or Allogeneic Hematop...Donald E. Tsai, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Results from a First-in-Human, Proof-of-Concept Phase 1 Trial in Pretreated B-Cell Malignancies for Loxo-305, a Next-Generation, Highly Selective, Non-Covalent BTK Inh...Donald E. Tsai, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Press Mentions
Atara Biotherapeutics Announces Two Presentations at 59th American Society of Hematology Annual Meeting, Including Positive Interim Results from a Multicenter Expanded Access Study of ATA129 for Patients with Epstein-Barr Virus (EBV)-Associated CancersNovember 1st, 2017
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
